Seres Therapeutics GAAP EPS of -$1.63 misses by $0.63, revenue of $0.59M misses by $5.76M (MCRB:NASDAQ)
Seres Therapeutics (MCRB) reported Q3 GAAP EPS of -$1.63, missing estimates by $0.63. Revenue was $0.59M, down $5.76M from expectations, despite a 68.6% year-over-year increase. Shares fell 11% post-market.
How this was made
The 30-second read
Why it matters
The earnings miss triggered an 11% pre‑market decline, indicating immediate negative market reaction.
Market read
The primary earnings disclosure for a micro‑cap biotech creates short‑term trading relevance due to the sizable pre‑market move.
What to watch
Potential upcoming clinical data releases or partnership announcements could offset the earnings disappointment.
Background
Seres Therapeutics (NASDAQ:MCRB) released its Q3 2026 earnings, reporting a GAAP loss per share of $1.63 and revenue of $0.59 million, both below consensus expectations.
Ticker impact
Q3 GAAP EPS of -$1.63 and revenue of $0.59M were disclosed, both missing expectations and causing an 11% pre‑market drop.
likely further downside as investors price in weaker earnings and lower revenue guidance
The miss on both EPS and revenue is material for a micro‑cap biotech; the stock already fell 11% pre‑market, suggesting continued sell pressure.
Market effects
Biotech sector may see modest pullback as earnings miss highlights execution risk for early‑stage therapeutics.
Limited to U.S. biotech investors; no broader regional effect.
Low; the company is a small cap with niche exposure.
Counterpoint
If the miss is viewed as a temporary setback and the pipeline remains strong, the stock could be a short‑term buying opportunity on the dip.
Key entities
- companySeres Therapeutics, Inc.
Biotech firm focused on microbiome‑based therapeutics, listed on NASDAQ under MCRB.
